KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Income from Continuing Operations (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Income from Continuing Operations for 16 consecutive years, with 141624000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 203.37% to 141624000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 316889000.0, a 28.64% decrease, with the full-year FY2025 number at 316889000.0, down 28.64% from a year prior.
  • Income from Continuing Operations was 141624000.0 for Q4 2025 at Halozyme Therapeutics, down from 175258000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 175258000.0 in Q3 2025 to a low of 141624000.0 in Q4 2025.
  • A 5-year average of 67536600.0 and a median of 75789500.0 in 2023 define the central range for Income from Continuing Operations.
  • Biggest YoY gain for Income from Continuing Operations was 557.07% in 2021; the steepest drop was 321.21% in 2021.
  • Halozyme Therapeutics' Income from Continuing Operations stood at 66770000.0 in 2021, then decreased by 13.58% to 57702000.0 in 2022, then surged by 47.98% to 85386000.0 in 2023, then surged by 60.46% to 137012000.0 in 2024, then crashed by 203.37% to 141624000.0 in 2025.
  • Per Business Quant, the three most recent readings for HALO's Income from Continuing Operations are 141624000.0 (Q4 2025), 175258000.0 (Q3 2025), and 165127000.0 (Q2 2025).